(Q44160396)

30 November 2017

title

Kidney cancer: overall survival is an unsuitable primary end point (English)

1 reference

30 November 2017

1 reference

Giuseppe Di Lorenzo

1

1 reference

30 November 2017

Carlo Buonerba

series ordinal

2

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

30 November 2017

published in

Nature Reviews Urology

1 reference

30 November 2017

volume

7

1 reference

30 November 2017

issue

7

1 reference

30 November 2017

page(s)

367-368

1 reference

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.84

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20616795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2010.84

1 reference

Dimensions Publication ID

30 November 2017

1034239980

0 references

1 reference